The CMR GUIDE trial didn’t meet its primary endpoint but did point to possible positives, especially in younger patients.

Among patients with nonobstructive hypertrophic cardiomyopathy (HCM), the selective cardiac myosin inhibitor aficamten ...

The US Food and Drug Administration has granted an expanded indication to tirzepatide (Mounjaro) for reducing major adverse ...

At TCT 2025, Jeff Popma interviews Sahar Samimi and Sachin Goel about the simultaneous presentation and publication of their ...

Because of the low number of events in the trial, the findings are thought-provoking but not definitive, one expert says.

Compared with standard treatment, an abbreviated regimen was associated with more relapses but didn’t compromise safety.

The agency says the company has reported 37 serious injuries and three deaths related to the issue as of August 17.

While there’s no harm in discontinuing for patients who’ve yet to develop ASCVD by age 75, the trial also found no clear ...

Boston Scientific has reported one serious injury, but no deaths, related to the defect. Today the FDA announced a Class I ...

There was a modest gain in the number of days alive and at home after the operation, with a significant savings in blood ...

A drop in hemoglobin isn’t cause to panic but may warrant action based on patient-specific factors, says Husam Abdel-Qadir.

TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of ...